Anne De Paepe

Medicine · Health Sciences

43h-index25.3kcitations146works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Neuroblastoma Research and Treatments(43), Cancer-related Molecular Pathways(15), Acute Myeloid Leukemia Research(13), Cancer, Hypoxia, and Metabolism(8), Chronic Myeloid Leukemia Treatments(8)

Publications146 total

Supplementary Methods, Tables 1-2, Figures 1-3 from Functional Analysis of the p53 Pathway in Neuroblastoma Cells Using the Small-Molecule MDM2 Antagonist Nutlin-3
2023Open Access
Data from Functional Analysis of the p53 Pathway in Neuroblastoma Cells Using the Small-Molecule MDM2 Antagonist Nutlin-3
2023Open Access
Data from Functional Analysis of the p53 Pathway in Neuroblastoma Cells Using the Small-Molecule MDM2 Antagonist Nutlin-3
2023Open Access
Supplementary Table 2 from Meta-analysis of Neuroblastomas Reveals a Skewed <i>ALK</i> Mutation Spectrum in Tumors with <i>MYCN</i> Amplification
2023Open Access
Data from Meta-analysis of Neuroblastomas Reveals a Skewed <i>ALK</i> Mutation Spectrum in Tumors with <i>MYCN</i> Amplification
2023Open Access
Supplementary Table 1 from Meta-analysis of Neuroblastomas Reveals a Skewed <i>ALK</i> Mutation Spectrum in Tumors with <i>MYCN</i> Amplification
2023Open Access
Supplementary Table 1 from Meta-analysis of Neuroblastomas Reveals a Skewed <i>ALK</i> Mutation Spectrum in Tumors with <i>MYCN</i> Amplification
2023Open Access
Supplementary Table 2 from Meta-analysis of Neuroblastomas Reveals a Skewed <i>ALK</i> Mutation Spectrum in Tumors with <i>MYCN</i> Amplification
2023Open Access
Data from Meta-analysis of Neuroblastomas Reveals a Skewed <i>ALK</i> Mutation Spectrum in Tumors with <i>MYCN</i> Amplification
2023Open Access
Data from Small-Molecule MDM2 Antagonists as a New Therapy Concept for Neuroblastoma
2023Open Access
Supplementary Figures 1-5 from Small-Molecule MDM2 Antagonists as a New Therapy Concept for Neuroblastoma
2023Open Access
Data from Small-Molecule MDM2 Antagonists as a New Therapy Concept for Neuroblastoma
2023Open Access
Supplementary Figures 1-5 from Small-Molecule MDM2 Antagonists as a New Therapy Concept for Neuroblastoma
2023Open Access
Leapfrogging with technology: introduction of a monitoring platform to support a large-scale Ebola vaccination program in Rwanda
Human Vaccines & Immunotherapeutics·2021· 5 citedOpen Access
ESRA19-0235 Screening for psychosocial variables that predict chronic postsurgical pain
2019
Pre- and post-testing counseling considerations for the provision of expanded carrier screening: exploration of European geneticists’ views
BMC Medical Ethics·2017· 22 citedOpen Access
Attitudes of European Geneticists Regarding Expanded Carrier Screening
Journal of Obstetric, Gynecologic & Neonatal Nursing·2016· 30 cited
Clinical utility gene card for: Hereditary thoracic aortic aneurysm and dissection including next-generation sequencing-based approaches
European Journal of Human Genetics·2015· 30 citedOpen Access
Attitudes of cystic fibrosis patients and parents toward carrier screening and related reproductive issues
European Journal of Human Genetics·2015· 28 citedOpen Access
Table 3. [Selected EFEMP2 Allelic Variants].
2015
page 1 of 8Next →

Frequent Co-authors

Frank Speleman(31), Jo Vandesompele(29), Nadine Van Roy(16), Bruce Poppe(11), Katleen De Preter(10), Filip Pattyn(8), Ludwine Messiaen(8), Geneviève Laureys(8), Nurten Yigit(8), Jasmien Hoebeeck(6), Tom Van Maerken(6), Joëlle Vermeulen(6), Frank Speleman(5), Alexander Schramm(5), Heidi Van Limbergen(5), Nicole Dastugue(5), Evi Michels(5), Geert Mortier(4), Angelika Eggert(4), Jan Cools(4)